Session » Infection-related Rheumatic Disease Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0800

Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications

9:00AM-10:30AM: Abstract Number: 0793

Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation

9:00AM-10:30AM: Abstract Number: 0780

B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients

9:00AM-10:30AM: Abstract Number: 0783

Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 0784

Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis

9:00AM-10:30AM: Abstract Number: 0788

Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study

9:00AM-10:30AM: Abstract Number: 0779

Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab

9:00AM-10:30AM: Abstract Number: 0786

Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0785

Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study

9:00AM-10:30AM: Abstract Number: 0791

Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy

9:00AM-10:30AM: Abstract Number: 0801

Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry

9:00AM-10:30AM: Abstract Number: 0794

Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 0804

Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study

9:00AM-10:30AM: Abstract Number: 0797

Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease

9:00AM-10:30AM: Abstract Number: 0802

Is There Any Relationship Between Helicobacter Pylori and Rheumatoid Arthritis?

9:00AM-10:30AM: Abstract Number: 0806

Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression

9:00AM-10:30AM: Abstract Number: 0782

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab

9:00AM-10:30AM: Abstract Number: 0803

Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis

9:00AM-10:30AM: Abstract Number: 0795

Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications

9:00AM-10:30AM: Abstract Number: 0792

Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)

9:00AM-10:30AM: Abstract Number: 0787

Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine

9:00AM-10:30AM: Abstract Number: 0805

Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia

9:00AM-10:30AM: Abstract Number: 0781

Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose

9:00AM-10:30AM: Abstract Number: 0796

SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?

9:00AM-10:30AM: Abstract Number: 0799

Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study

9:00AM-10:30AM: Abstract Number: 0790

Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study

9:00AM-10:30AM: Abstract Number: 0789

The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study

9:00AM-10:30AM: Abstract Number: 0798

Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].